Mouse Anti-HSD17B4 Monoclonal Antibody (CBFYH-3206) (CBMAB-H0437-FY)

Arai, N., Hattori, N., Yamashita, S., Liu, Y. Y., Ebata, T., Takeuchi, C., ... & Ushijima, T. (2023). HSD17B4 methylation enhances glucose dependence of BT-474 breast cancer cells and increases lapatinib sensitivity. Breast Cancer Research and Treatment, 1-12.

Chen, S., Du, L., Lei, Y., Lin, Y., Chen, S., & Liu, Y. (2021). Two novel HSD17B4 heterozygous mutations in association with D-Bifunctional protein deficiency: a case report and literature review. Frontiers in Pediatrics, 9, 679597.

Lee, S. A., Lee, J., Kim, K., Moon, H., Min, C., Moon, B., ... & Park, D. (2021). The peroxisomal localization of Hsd17b4 is regulated by its interaction with phosphatidylserine. Molecules and Cells, 44(4), 214.

Yamashita, S., Hattori, N., Fujii, S., Yamaguchi, T., Takahashi, M., Hozumi, Y., ... & Mukai, H. (2020). Multi-omics analyses identify HSD17B4 methylation-silencing as a predictive and response marker of HER2-positive breast cancer to HER2-directed therapy. Scientific Reports, 10(1), 15530.

Huang, H., Liu, R., Huang, Y., Feng, Y., Fu, Y., Chen, L., ... & Chen, Y. (2020). Acetylation-mediated degradation of HSD17B4 regulates the progression of prostate cancer. Aging (Albany NY), 12(14), 14699.

Zhang, X., Yang, H., Zhang, J., Gao, F., & Dai, L. (2020). HSD17B4, ACAA1, and PXMP4 in peroxisome pathway are down-regulated and have clinical significance in non-small cell lung cancer. Frontiers in Genetics, 11, 273.

Matsuda, Y., Morino, H., Miyamoto, R., Kurashige, T., Kume, K., Mizuno, N., ... & Kawakami, H. (2020). Biallelic mutation of HSD17B4 induces middle age–onset spinocerebellar ataxia. Neurology Genetics, 6(1).

Violante, S., Achetib, N., van Roermund, C. W., Hagen, J., Dodatko, T., Vaz, F. M., ... & Houten, S. M. (2019). Peroxisomes can oxidize medium-and long-chain fatty acids through a pathway involving ABCD3 and HSD17B4. The FASEB Journal, 33(3), 4355.

Pan, L. C., Xiao, H. Y., Yin, W. J., & Lin, Z. (2018). Correlation between HSD17B4 expression in rat liver cancer tissues and inflammation or proliferation. Eur Rev Med Pharmacol Sci, 22(11), 3386-3393.

Ko, H. K., Berk, M., Chung, Y. M., Willard, B., Bareja, R., Rubin, M., ... & Sharifi, N. (2018). Loss of an androgen-inactivating and isoform-specific HSD17B4 splice form enables emergence of castration-resistant prostate cancer. Cell reports, 22(3), 809-819.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols